SGS Announces Formulation and Stability Testing Services, New Labs
SGS to offer program-based stability testing services for biopharmaceuticals from Wokingham, UK facility.
SGS Life Science Services has announced new services for the integrated formulation and stability testing service for biologics that offer clients a program approach rather than project-based support. The services encompass pre/formulation preparation and testing, release/stability testing, troubleshooting expertise, higher order characterization and license application supporting studies, as well as stability indicating methods (forced degradation), administration support studies (such as extractables and leachables) and shipment support studies, according to a company press release.
The studies will be hosted by the SGS Life Science Services laboratories in Wokingham, UK; more than 7,000 sq ft of laboratories were built to accommodate the new services.
One new offering includes an upfront shipping route risk assessment, followed by conditioning and comprehensive product quality testing. The conditioning can be performed using an onsite automated thermal cycling chamber which can control temperature and humidity to a defined set point, such as ‑5°C, 0°C or +55°C/75 % RH, for anticipated exposure times. The chamber is also capable of supporting customer-specific requests and automated temperature cycling studies with a qualified operating range of ‑70°C to +180 °C and 10 % RH to 98 % RH.
SGS recently announced plans to open its fifth North American Life Science Services laboratory in Carson, Calif. This investment will establish a Life Science Services GMP/GLP laboratory, with the ability to provide microbiological testing and bioanalytical services. The new facility will encompass 8,000 sq ft, of which 6,000 sq ft will be dedicated laboratory space and remaining space for offices, conference rooms, and client records. The new facility is projected to open early in the third quarter of 2014 and will initially employ seven scientific staff, with room to expand as the demand grows.
Source: SGS Life Science Services
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
